PAM
PGNX

Princeton Alpha Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Princeton Alpha Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-23,774
Closed -$100K – 1017
2016
Q2 		$100K Buy
+23,774
New +$115K 0.02% 729
2015
Q1 		– Sell
-19,703
Closed -$149K – 941
2014
Q4 		$149K Buy
+19,703
New +$118K 0.04% 605

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Princeton Alpha Management's PGNX Position: Q3 2016 in Review

Princeton Alpha Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2016, closing a stake of 23,774 shares — an estimated $100K sold.

Princeton Alpha Management first reported a position in PGNX in Q4 2014 and held it in 2 quarters. The position peaked at $149K in Q4 2014. 115 funds tracked by Wall St. Rank hold PGNX as of Q3 2016.

  • Princeton Alpha Management reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2016 after selling out during the quarter.
  • Princeton Alpha Management sold 23,774 Progenics Pharmaceuticals Inc shares in Q3 2016, an estimated $100K.
  • Princeton Alpha Management first reported a position in Progenics Pharmaceuticals Inc in Q4 2014 and held it in 2 quarters.
  • Princeton Alpha Management's Progenics Pharmaceuticals Inc position peaked at $149K in Q4 2014.
  • 115 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2016.

Based on Princeton Alpha Management's 13F filing for Q3 2016, filed 10 Nov 2016.